Literature DB >> 20019984

Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer.

Venu Chalasani1, Joseph L Chin, Jonathan I Izawa.   

Abstract

Bladder cancer can be classified histologically as urothelial or non-urothelial. Urothelial cancer has a propensity for divergent differentiation, which has increasingly been recognized in recent years due to heightened awareness and improved immunohistochemistry techniques. Furthermore, the recent World Health Organization classification of urothelial cancers improved clarity on this issue, with its listing of 13 histologic variants of urothelial cancer. The divergent differentiation patterns include, amongst others, squamous, glandular, micropapillary, nested, lymphepithelioma-like, plasmacytoid and sarcomatoid variants of urothelial cancer. Attempts to quantify the amount of divergent differentiation present, such as using the nonconventional differentiation number, have been made recently, which will improve the ability to compare publications from different centres. Genetic-based studies have indicated that the histologic variants of urothelial cancer arise from a common clonal precursor. Mostly, the current evidence suggests that urothelial cancer with divergent differentiation has a worse prognosis when compared with pure urothelial cancer. This article will review the current literature on variant histologies of urothelial cancer, and well as new developments in pure squamous cell carcinoma, small cell carcinoma and adenocarcinoma of the bladder.

Entities:  

Year:  2009        PMID: 20019984      PMCID: PMC2792446          DOI: 10.5489/cuaj.1195

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  62 in total

1.  Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases.

Authors:  Kien T Mai; Paul C Park; Hossein M Yazdi; Eric Saltel; Seyda Erdogan; William A Stinson; Ilias Cagiannos; Christopher Morash
Journal:  Eur Urol       Date:  2006-01-18       Impact factor: 20.096

2.  Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients.

Authors:  Mohamed S Zaghloul; Akram Nouh; Mohamed Nazmy; Samy Ramzy; Ashraf S Zaghloul; Mohamed Abou Sedira; Ehab Khalil
Journal:  Urol Oncol       Date:  2006 Jan-Feb       Impact factor: 3.498

Review 3.  Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: a review of etiological features, natural history, and management.

Authors:  Medhat El-Sebaie; Mohamed Saad Zaghloul; Grahame Howard; Alaa Mokhtar
Journal:  Int J Clin Oncol       Date:  2005-02       Impact factor: 3.402

4.  A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder.

Authors:  N Gad el Mawla; M A Mansour; S Eissa; N M Ali; I Elattar; M R Hamza; H Khaled; N Habboubi; I Magrath; I Elsebai
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

5.  Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study.

Authors:  Wojciech Jozwicki; Jan Domaniewski; Zdzislaw Skok; Zbigniew Wolski; Ewa Domanowska; Grazyna Jozwicka
Journal:  Urology       Date:  2005-11       Impact factor: 2.649

6.  Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control.

Authors:  M S Zaghloul; H K Awwad; H H Akoush; S Omar; O Soliman; I el Attar
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.

Authors:  Craig G Rogers; Ganesh S Palapattu; Shahrokh F Shariat; Pierre I Karakiewicz; Patrick J Bastian; Yair Lotan; Amit Gupta; Amnon Vazina; Amiel Gilad; Arthur I Sagalowsky; Seth P Lerner; Mark P Schoenberg
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

8.  Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases.

Authors:  Isabel Alvarado-Cabrero; Francisca I Sierra-Santiesteban; Alejandra Mantilla-Morales; Dulce Ma Hernández-Hernandez
Journal:  Ann Diagn Pathol       Date:  2005-02       Impact factor: 2.090

Review 9.  The pathology of bladder cancer.

Authors:  Victor E Reuter
Journal:  Urology       Date:  2006-03       Impact factor: 2.649

10.  The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

Authors:  Ashish M Kamat; Jason R Gee; Colin P N Dinney; H Barton Grossman; David A Swanson; Randall E Millikan; Michelle A Detry; Tracy L Robinson; Louis L Pisters
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

View more
  52 in total

1.  Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.

Authors:  Hikmat A Al-Ahmadie; Gopa Iyer; Byron H Lee; Sasinya N Scott; Rohit Mehra; Aditya Bagrodia; Emmet J Jordan; Sizhi Paul Gao; Ricardo Ramirez; Eugene K Cha; Neil B Desai; Emily C Zabor; Irina Ostrovnaya; Anuradha Gopalan; Ying-Bei Chen; Samson W Fine; Satish K Tickoo; Anupama Gandhi; Joseph Hreiki; Agnès Viale; Maria E Arcila; Guido Dalbagni; Jonathan E Rosenberg; Bernard H Bochner; Dean F Bajorin; Michael F Berger; Victor E Reuter; Barry S Taylor; David B Solit
Journal:  Nat Genet       Date:  2016-02-22       Impact factor: 38.330

2.  Perirectal recurrence and intraperitoneal dissemination of urothelial carcinoma as plasmacytoid variant: clinical-imaging-histological findings.

Authors:  Miguel Angel Arrabal-Polo; María Del Carmen Cano-García; Paolo Fabiano; Verónica Martínez-Pagán; Matías Barayobre; Javier González García
Journal:  Int Urol Nephrol       Date:  2015-06-07       Impact factor: 2.370

3.  2018 CUA Abstracts.

Authors: 
Journal:  Can Urol Assoc J       Date:  2018-06       Impact factor: 1.862

4.  [Non-invasive and invasive urothelial tumours: special challenges in uropathological diagnostics].

Authors:  N T Gaisa; K Lindemann-Docter
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

5.  Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.

Authors:  Shuxia Qin; Lidan Yi; Sini Li; Chongqing Tan; Xiaohui Zeng; Liting Wang; Ye Peng; Xiaomin Wan
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

6.  Bladder preserving approach for liposarcomatoid variant of transitional urothelial carcinoma.

Authors:  S K Singh; Ankur Mittal; Abhinandan Mukhopadhyay; Nandita Kakkar; Debajyoti Chatterjee
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

Review 7.  Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).

Authors:  Jorge García; Lucia Santomé; Urbano Anido; Ovidio Fernández-Calvo; Javier Afonso-Afonso; Martín Lázaro; Ana Medina; Sergio Vázquez Estévez
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

8.  Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.

Authors:  Emmanuel I Papadopoulos; Andreas Scorilas
Journal:  Clin Transl Sci       Date:  2015-09-10       Impact factor: 4.689

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?

Authors:  R Morales-Barrera; C Suárez; C Valverde; I Nuñez; X Maldonado; J Morote; J Carles
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.